top of page

Our Platform

An Industry Disruptor

Gut Microbiota derived and optimised signaling molecules that maintain immune tolerance (Nutraceuticals) but can also further direct a tailored immune function (Pharmaceuticals).

​

The Mechanism of Action for our therapeutics is via pattern recognition receptors on antigen presenting cells that polarise T cells with MHC class II molecules from Bifidobacterium spp. Upon presentation, our bioactives induce the tailored activation and proliferation of T cells that control the Th1/Th2 physiologic balance.

The Discovery Platform-iKAR

AI powered platform for the de novo design of microbiome derived signaling molecules

We integrate sequencing & informatics technologies with synthetic biology to identify and advance promising molecules 

bottom of page